Loading a Novel Anti-biofilm Compound into Polyurethane Foam for Use in Negative Pressure Wound Therapy Skip to main content
Utah's Foremost Platform for Undergraduate Research Presentation
2020 Abstracts

Loading a Novel Anti-biofilm Compound into Polyurethane Foam for Use in Negative Pressure Wound Therapy

Rawson, Kaden; Nueberger, Travis; Looper, Ryan; Sebahar, Paul; Williams, Dustin (University of Utah)

Faculty Advisor: Williams, Dustin (Engineering, Bioengineering)

Negative pressure wound therapy (NPWT) is commonly used to treat high energy, traumatic battlefield-related injuries, typically caused by an explosion. NPWT may be applied in the field at the time of injury or in the operating room as a therapeutic measure. Wounds are susceptible to contamination from the soil, which contains high amounts of bacteria (>10^9 colony forming units (CFU)/g of material). Greater than 99% of wild-type bacteria favor the biofilm phenotype in the natural world. Biofilms are aggregates of bacteria that are more resistant to traditional antibiotics due to their altered phenotypic and metabolic expressions. Thus, developed biofilms can potentially contaminate these wounds and lead to chronic infection. Furthermore, the lattice structure of polyurethane (PU) foam used in NPWT can potentially harbor and encourage increased biofilm growth. Since the introduction of NPWT as a standard of care for soldiers in 2004, "superficial and deep infections of soft tissue remain a clinical concern after sustaining combat-related trauma [while] using NPWT." To date, GRANUFOAM Silver by KCI is the only variation of PU foam for NPWT that possesses any degree of antimicrobial efficacy. However, silver nanoparticles are minimally effective against biofilms. Thus, the goal of this project is to develop a PU foam that is loaded with a biofilm-specific antimicrobial compound, CZ-01179 in order to decrease the rate of infection when NPWT is utilized in the field of battle.

To date, two prototypes have been developed: One prototype (V1) relies on THF and H2O to coat the Pu foam with CZ-01179 while the second prototype (V2) relies on a hydrogel scaffold to provide a sustained release of CZ-01179 over 24 hours. V1 has been shown to reduce MRSA AND A. baumanii by 7 Log10 CFU during in vitro dilution testing compared to a 1 Log10 reduction produced by GRANUFOAM Silver.